Ultimovacs ASA's Phase II FOCUS trial evaluating UV1 in combination with pembrolizumab for head and neck squamous cell carcinoma (HNSCC) did not meet its primary or secondary endpoints. The trial, an investigator-sponsored study led by Professor Mascha Binder at the University of Halle-Wittenberg in Germany, aimed to assess the clinical performance of UV1 vaccination when added to standard pembrolizumab treatment.
The FOCUS trial (NCT05075122) was a randomized, open-label Phase II clinical trial involving 75 patients with metastatic or recurrent PD-L1 positive HNSCC. Patients were randomized in a 2:1 ratio, with 50 receiving UV1 and pembrolizumab, and 25 receiving pembrolizumab alone. The primary endpoint was progression-free survival (PFS) rate at 6 months. Secondary endpoints included overall survival (OS), objective response rate (ORR), duration of response (DOR), and safety.
Topline data indicated that the addition of UV1 to pembrolizumab did not result in clinical benefits in progression-free survival or overall survival. However, UV1 maintained a positive safety profile, consistent with previous studies, with similar adverse events observed in both the treatment and control arms.
About UV1
UV1 is a universal cancer vaccine designed to stimulate a T cell response against telomerase, a target present in a significant majority (85-90%) of cancers. The vaccine comprises synthetic peptides representing a sequence in the reverse transcriptase subunit of telomerase (hTERT), which are designed to induce CD4+ T cells. These CD4+ T cells are believed to provide inflammatory signals and T cell support crucial for triggering a strong anti-tumor immune response.
Following intradermal injection, antigen-presenting cells (APCs) in the skin are exposed to the vaccine peptides. These APCs process the peptides and present vaccine epitopes on Human Leukocyte Antigen (HLA) molecules to naive T cells in the lymph nodes. Activated vaccine-specific T cells then enter the circulation and search for cells displaying their cognate antigen in the context of HLA molecules. The UV1 peptides contain several epitopes, shown to be non-restrictive in terms of HLA alleles for presentation, potentially enabling broad population utilization without HLA pre-screening.
Ongoing Clinical Development
Ultimovacs is continuing to investigate the safety and efficacy of UV1 in a comprehensive clinical development program across various cancer indications and immunotherapy combinations. This program includes five randomized Phase II clinical trials in melanoma, mesothelioma, head and neck cancer, ovarian cancer, and non-small cell lung cancer, with over 640 patients enrolled in the U.S., Europe, and Australia.
